KR20090125833A - 건선 및 다른 피부 질환의 치료를 위한 Ｈｈ/Ｓｍｏ 신호의 선택적 억제제의 용도 - Google Patents
건선 및 다른 피부 질환의 치료를 위한 Ｈｈ/Ｓｍｏ 신호의 선택적 억제제의 용도 Download PDFInfo
- Publication number
- KR20090125833A KR20090125833A KR1020097022024A KR20097022024A KR20090125833A KR 20090125833 A KR20090125833 A KR 20090125833A KR 1020097022024 A KR1020097022024 A KR 1020097022024A KR 20097022024 A KR20097022024 A KR 20097022024A KR 20090125833 A KR20090125833 A KR 20090125833A
- Authority
- KR
- South Korea
- Prior art keywords
- cyclopamine
- treatment
- skin
- medicine
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 61
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 31
- 208000017520 skin disease Diseases 0.000 title claims description 7
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 claims abstract description 100
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 claims abstract description 99
- 230000004069 differentiation Effects 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 230000005764 inhibitory process Effects 0.000 claims abstract description 4
- 230000003902 lesion Effects 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 8
- 210000001339 epidermal cell Anatomy 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000007933 dermal patch Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 14
- 208000002506 Darier Disease Diseases 0.000 claims 1
- 241000027355 Ferocactus setispinus Species 0.000 claims 1
- 206010023369 Keratosis follicular Diseases 0.000 claims 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000008034 disappearance Effects 0.000 claims 1
- 201000004607 keratosis follicularis Diseases 0.000 claims 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 24
- 239000003246 corticosteroid Substances 0.000 abstract description 23
- 239000000203 mixture Substances 0.000 abstract description 16
- 230000024245 cell differentiation Effects 0.000 abstract description 15
- 210000004881 tumor cell Anatomy 0.000 abstract description 15
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 230000006907 apoptotic process Effects 0.000 abstract description 7
- 230000006698 induction Effects 0.000 abstract description 6
- 210000004927 skin cell Anatomy 0.000 abstract description 2
- 230000006735 deficit Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000006071 cream Substances 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 24
- 102000001301 EGF receptor Human genes 0.000 description 18
- 108060006698 EGF receptor Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 15
- 229960001334 corticosteroids Drugs 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 206010004146 Basal cell carcinoma Diseases 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 11
- 229960004703 clobetasol propionate Drugs 0.000 description 9
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 208000007660 Residual Neoplasm Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 208000031513 cyst Diseases 0.000 description 5
- 206010027145 Melanocytic naevus Diseases 0.000 description 4
- 208000007256 Nevus Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 101100207366 Curvularia clavata TR02 gene Proteins 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000289669 Erinaceus europaeus Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010043275 Teratogenicity Diseases 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000012056 cerebral malformation Diseases 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000211 teratogenicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 206010048409 Brain malformation Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000001913 Lamellar ichthyosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 241000489523 Veratrum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000000185 follicular epithelial cell Anatomy 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940096717 pamine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2001/000027 WO2002078703A1 (en) | 2001-07-02 | 2001-07-02 | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| TRPCT/TR02/00017 | 2002-04-19 | ||
| PCT/TR2002/000017 WO2002078704A1 (en) | 2001-07-02 | 2002-04-19 | Use of cyclopamine in the treatment of psoriasis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087024137A Division KR20080094739A (ko) | 2002-04-19 | 2003-03-17 | 코르티코스테로이드 및 Ｈｈ/Ｓｍｏ 신호의 억제제를 포함하는 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090125833A true KR20090125833A (ko) | 2009-12-07 |
Family
ID=21619326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097022024A Ceased KR20090125833A (ko) | 2001-07-02 | 2003-03-17 | 건선 및 다른 피부 질환의 치료를 위한 Ｈｈ/Ｓｍｏ 신호의 선택적 억제제의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| EP (4) | EP2862570A1 (OSRAM) |
| JP (3) | JP2004536045A (OSRAM) |
| KR (1) | KR20090125833A (OSRAM) |
| CN (2) | CN1525859B (OSRAM) |
| AT (2) | ATE305300T1 (OSRAM) |
| AU (1) | AU2001272892B8 (OSRAM) |
| BR (1) | BR0117063A (OSRAM) |
| CA (1) | CA2452151C (OSRAM) |
| DE (2) | DE60113733T2 (OSRAM) |
| DK (2) | DK1401438T3 (OSRAM) |
| ES (3) | ES2534400T3 (OSRAM) |
| PT (1) | PT1411938E (OSRAM) |
| RU (1) | RU2312661C2 (OSRAM) |
| WO (2) | WO2002078703A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| EP2862570A1 (en) * | 2001-07-02 | 2015-04-22 | Sinan Tas | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| EP1411938B1 (en) * | 2001-07-02 | 2005-07-06 | Tas, Sinan | Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis |
| US20170326118A1 (en) | 2001-07-02 | 2017-11-16 | Sinan Tas | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells |
| US8653083B2 (en) | 2005-08-22 | 2014-02-18 | The Johns Hopkins University | Hedgehog pathway antagonists to treat disease |
| EP2511298B1 (en) | 2005-10-31 | 2019-01-16 | Oncomed Pharmaceuticals, Inc. | Compositions and Methods for Treating Cancer based on human FZD receptors |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| WO2008070357A2 (en) * | 2006-10-31 | 2008-06-12 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Smoothened polypeptides and methods of use |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| WO2008109184A1 (en) * | 2007-03-07 | 2008-09-12 | Infinity Pharmaceuticals, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
| JP2010520310A (ja) * | 2007-03-07 | 2010-06-10 | インフィニティ・ディスカバリー・インコーポレイテッド | シクロパミンラクタム類似体及びその使用方法 |
| CN104059124A (zh) | 2007-12-27 | 2014-09-24 | 无限药品股份有限公司 | 立体选择性还原的方法 |
| CN101990542A (zh) * | 2008-02-08 | 2011-03-23 | 德克萨斯大学董事会 | 环巴胺酒石酸盐及其用途 |
| TWI506037B (zh) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| US20110275576A1 (en) * | 2009-01-06 | 2011-11-10 | Utah State University | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents |
| JP2009143963A (ja) * | 2009-03-25 | 2009-07-02 | Sinan Tas | 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物 |
| JP6141015B2 (ja) | 2009-08-05 | 2017-06-07 | インフィニティ ファーマスーティカルズ、インク． | シクロパミン類似体の酵素によるアミノ基転移 |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| WO2011123785A2 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| EP2911691B1 (en) | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| WO2015096654A1 (zh) * | 2013-12-26 | 2015-07-02 | 中国科学院上海生命科学研究院 | Shh信号通路特异性抑制剂的应用 |
| HRP20251395T1 (hr) | 2015-06-04 | 2026-02-13 | Sol-Gel Technologies Ltd. | Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba |
| US20170231968A1 (en) * | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Method for relief of and treatment of pruritus |
| CN117940170A (zh) | 2021-09-13 | 2024-04-26 | 辛南·塔斯 | 有效干预人类衰老和衰老疾病及其效果 |
| CN114292279B (zh) * | 2022-01-07 | 2023-05-09 | 吉林省农业科学院 | 一种藜芦抗癌有效成分环杷明提取与分离方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851993A (en) * | 1994-06-13 | 1998-12-22 | Biotie Therapies Ltd. | Suppression of tumor cell growth by syndecan-1 ectodomain |
| CA2326654C (en) * | 1998-04-09 | 2010-11-09 | Johns Hopkins University School Of Medicine | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
| RU2232758C2 (ru) * | 1998-09-23 | 2004-07-20 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием |
| US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| ES2233383T3 (es) * | 1999-06-08 | 2005-06-16 | Lorantis Limited | Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog. |
| CA2386190C (en) * | 1999-10-13 | 2009-04-14 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
| AU1935801A (en) * | 1999-11-30 | 2001-06-12 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| CU23175A1 (es) * | 2000-07-17 | 2006-09-22 | Ct De Investigacion Y Desarrol | Formulacion liposomica de propionato de clobetasol |
| EP1411938B1 (en) * | 2001-07-02 | 2005-07-06 | Tas, Sinan | Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis |
| EP2862570A1 (en) * | 2001-07-02 | 2015-04-22 | Sinan Tas | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
-
2001
- 2001-07-02 EP EP20140196071 patent/EP2862570A1/en not_active Withdrawn
- 2001-07-02 DK DK01952097T patent/DK1401438T3/da active
- 2001-07-02 EP EP05008758A patent/EP1561464A3/en not_active Withdrawn
- 2001-07-02 ES ES10163813.8T patent/ES2534400T3/es not_active Expired - Lifetime
- 2001-07-02 AU AU2001272892A patent/AU2001272892B8/en not_active Ceased
- 2001-07-02 EP EP01952097A patent/EP1401438B1/en not_active Revoked
- 2001-07-02 CN CN018234429A patent/CN1525859B/zh not_active Expired - Fee Related
- 2001-07-02 ES ES01952097T patent/ES2250434T3/es not_active Expired - Lifetime
- 2001-07-02 AT AT01952097T patent/ATE305300T1/de not_active IP Right Cessation
- 2001-07-02 WO PCT/TR2001/000027 patent/WO2002078703A1/en not_active Ceased
- 2001-07-02 EP EP10163813.8A patent/EP2216022B1/en not_active Expired - Lifetime
- 2001-07-02 JP JP2002576969A patent/JP2004536045A/ja active Pending
- 2001-07-02 BR BR0117063-5A patent/BR0117063A/pt active Search and Examination
- 2001-07-02 CA CA2452151A patent/CA2452151C/en not_active Expired - Fee Related
- 2001-07-02 DE DE60113733T patent/DE60113733T2/de not_active Expired - Lifetime
-
2002
- 2002-04-19 PT PT02736467T patent/PT1411938E/pt unknown
- 2002-04-19 ES ES02736467T patent/ES2246011T3/es not_active Expired - Lifetime
- 2002-04-19 AT AT02736467T patent/ATE299022T1/de not_active IP Right Cessation
- 2002-04-19 WO PCT/TR2002/000017 patent/WO2002078704A1/en not_active Ceased
- 2002-04-19 RU RU2004103074/15A patent/RU2312661C2/ru not_active IP Right Cessation
- 2002-04-19 DK DK02736467T patent/DK1411938T3/da active
- 2002-04-19 DE DE60204966T patent/DE60204966T2/de not_active Expired - Lifetime
- 2002-04-19 CN CNB02813429XA patent/CN1230169C/zh not_active Expired - Fee Related
-
2003
- 2003-03-17 KR KR1020097022024A patent/KR20090125833A/ko not_active Ceased
-
2010
- 2010-02-10 JP JP2010028010A patent/JP5424923B2/ja not_active Expired - Fee Related
-
2013
- 2013-09-18 JP JP2013193304A patent/JP2014028834A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080096605A (ko) | 피부 질환의 치료를 위한 시클로파민 또는 다른 Ｈｈ/Ｓｍｏ 신호의 특이적 억제제의 용도 | |
| JP5424923B2 (ja) | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 | |
| Lin et al. | Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component | |
| AU2001272892A1 (en) | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors | |
| JP2003519654A (ja) | 脈管形成を抑制するためのエピガロカテキンガラートの使用 | |
| CA3115038A1 (en) | Egfr inhibitors for treating keratodermas | |
| CA2639904C (en) | Use of mimosine or a derivative thereof for treating the cutaneous effects of psoriasis and related skin disorders, and cosmetic or pharmaceutical composition containing same | |
| HK1096597A (en) | Use of cyclopamine in the treatment of psoriasis and other skin disorders | |
| Boateng et al. | 590 Biological and in-silico characterization of pyrazole and pyrazolone derivatives: Identifies novel anti-skin cancer, antioxidant and tyrosinase inhibitory agents | |
| Fuggetta et al. | Research Article Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20091021 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20091118 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100202 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20101203 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20100202 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20110302 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20101203 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20110601 Appeal identifier: 2011101001768 Request date: 20110302 |
|
| AMND | Amendment | ||
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20110401 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20110302 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20100802 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial |
Comment text: Report of Result of Re-examination before a Trial Patent event code: PB06011S01D Patent event date: 20110502 |
|
| J801 | Dismissal of trial |
Free format text: REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110302 Effective date: 20110601 |
|
| PJ0801 | Rejection of trial |
Patent event date: 20110601 Patent event code: PJ08011S01D Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision) Decision date: 20110601 Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2011101001768 Request date: 20110302 |